Budget Impact Analysis of Gene Therapies for Recessive Dystrophic Epidermolysis Bullosa

Back to Research Hub

Home
Research Hub
Budget Impact Analysis of Gene Therapies…

Budget Impact Analysis of Gene Therapies for Recessive Dystrophic Epidermolysis Bullosa

JAMA Dermatology·September 9

Dermatology Limited evidence Recessive Dystrophic Epidermolysis Bullosa Budget Impact Analysis Gene Therapy

Summary

What was studied

This economic evaluation assessed the budget impact of gene therapy for autosomal recessive dystrophic epidermolysis bullosa (RDEB).

Study limitations

The abstract provides insufficient detail to assess study methodology, assumptions, time horizon, or specific cost outcomes.

Caveats

Only the abstract was provided; no numerical results, sample size, time horizon, payer perspective, or model assumptions could be extracted. Summary fields are largely null as a result.
Study design label 'Budget Impact Analysis' is a health economics model, not a clinical trial; level of evidence reflects this accordingly.
The paper's DOI and publication date (September 9, 2026) are in the future relative to today's date (September 13, 2026), suggesting this is a very recently published article and full-text details may be limited or embargoed.

Related Questions

Explore related topics

What is the cost-effectiveness of gene therapy for recessive dystrophic epidermolysis bullosa?What gene therapies are currently approved or in trials for dystrophic epidermolysis bullosa?How do payers and health systems budget for ultra-rare disease gene therapies?

Publication Details

Year: 2026
Journal: JAMA Dermatology
Source: View article

Keep scrolling

More content below.

Up Next